Smith Adiel G, Kaiser Peter K
Dev Ophthalmol. 2016;55:246-51. doi: 10.1159/000431200. Epub 2015 Oct 26.
Ranibizumab is a recombinant, humanized, affinity-matured, monoclonal antibody Fab fragment against all isoforms of vascular endothelial growth factor-A, which was developed specifically for intraocular use. Ranibizumab has been extensively investigated in clinical trials on choroidal neovascularization from wet age-related macular degeneration and pathologic myopia, as well as macular edema due to diabetic retinopathy and retinal vein occlusion. Numerous randomized, controlled clinical trials have shown this medication to be effective in improving both vision as well as anatomical outcomes, and the medication has repeatedly shown to have an acceptable safety profile.
雷珠单抗是一种重组的、人源化的、亲和力成熟的抗血管内皮生长因子-A所有亚型的单克隆抗体Fab片段，专为眼内使用而研发。雷珠单抗已在湿性年龄相关性黄斑变性和病理性近视引起的脉络膜新生血管以及糖尿病性视网膜病变和视网膜静脉阻塞所致黄斑水肿的临床试验中得到广泛研究。大量随机对照临床试验表明，这种药物在改善视力和解剖学结果方面均有效，并且该药物反复显示出具有可接受的安全性。
